6-APB was first synthesized in 1993 by David Nicholls in hopes of finding a non-neurotoxic alternative to MDMA (which has the potential to induce neurotoxicity in humans).
What are the effects of 6-APB?
The subjective effects of 6-APB are generally described as being very similar to those of MDMA and 5-MAPB. It is often considered slightly more stimulating than 5-MAPB, while 5-MAPB is usually described as more euphoric.
6-APB has a significantly longer effect than MDMA. Most experiments last between 7 and 10 hours; while MDMA lasts between 3-6 hours and often leads to compulsive re-dosing. Both 5-MAPB and 6-APB have a less severe “comedown” than MDMA.
Currently, 6-APB is legal in: Belgium, France, Italy, Portugal, Spain, Netherlands, Greece, Japan, Russia, Mexico, Chile, Argentina, Suriname, Colombia, Brazil, Peru, Venezuela, Poland, Czech Republic, Hungary, Australia, New Zealand, United States of America, Saudi Arabia, Egypt, Turkey, Israel, Slovakia, Slovenia, Latvia, Estonia, Lithuania, Armenia, Uruguay, Canada, Tunisia among other